ArticleProceedings of the National Academy of Sciences of the United States of America2003
Solution structure of a functionally active fragment of decay-accelerating factor.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- DAF in diabetic patients is subject to glycation/inactivation at its active site residues.Molecular immunology · 2018Article
- Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode.The EMBO journal · 2016Article
- Equilibrium and kinetics of Sin Nombre hantavirus binding at DAF/CD55 functionalized bead surfaces.Viruses · 2014Article
- The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface.Journal of virology · 2012Article
- Interaction of decay-accelerating factor with echovirus 7.Journal of virology · 2010Article
- Tissue distribution and functional analysis of Sushi domain-containing protein 4.The American journal of pathology · 2010Article
- Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice.The American journal of pathology · 2009Article
- The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation.Acta crystallographica. Section D, Biological crystallography · 2009Article
- Interaction of decay-accelerating factor with coxsackievirus B3.Journal of virology · 2007Article
- Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.Protein science : a publication of the Protein Society · 2004Article
- Amino acid patterns within short consensus repeats define conserved duplicons shared by genes of the RCA complex.Journal of molecular evolution · 2004Article
- Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Backbone dynamics of complement control protein (CCP) modules reveals mobility in binding surfaces.Protein science : a publication of the Protein Society · 2004Article
- Complement regulation at the molecular level: the structure of decay-accelerating factor.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The second and third modules of human decay accelerating factor (DAF) are necessary and sufficient to accelerate decay of the classical pathway (CP) convertase of complement. No structure of a mammalian protein with decay-accelerating activity has been available to date. We therefore determined the solution structure of DAF modules 2 and 3 (DAF approximately 2,3). Structure-guided analysis of 24 mutants identified likely contact points between DAF and the CP convertase. Three (R96, R69, and a residue in the vicinity of L171) lie on DAF approximately 2,3's concave face. A fourth, consisting of K127 and nearby R100, is on the opposite face. Regions of module 3 remote from the semiflexible 2-3 interface seem not to be involved in binding to the CP convertase. DAF thus seems to occupy a groove on the CP convertase such that both faces of DAF close to the 2-3 junction (including a positively charged region that encircles the protein at this point) interact simultaneously. Alternative pathway convertase interactions with DAF require additional regions of CCP 3 lying away from the 2-3 interface, consistent with the established additional requirement of module 4 for alternative pathway regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.